Resident's Forum
FR-Ciclosporin as a First-Line Treatment in Epidermal Necrolysis
FR-Ciclosporina como tratamiento de primera línea en las necrólisis epidérmicas
D. Morgado-Carrasco, X. Fustà-Novell, P. Iranzo
Autor para correspondencia
Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, España
Leído
3817
Vecesse ha leído el artículo
1599
Total PDF
2218
Total HTML
Compartir estadísticas
array:24 [ "pii" => "S1578219019302021" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.01.005" "estado" => "S300" "fechaPublicacion" => "2019-09-01" "aid" => "2080" "copyright" => "Elsevier España, S.L.U. and AEDV" "copyrightAnyo" => "2018" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2019;110:601-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4 "formatos" => array:2 [ "HTML" => 2 "PDF" => 2 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731018304460" "issn" => "00017310" "doi" => "10.1016/j.ad.2018.01.014" "estado" => "S300" "fechaPublicacion" => "2019-09-01" "aid" => "2080" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2019;110:601-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 172 "formatos" => array:3 [ "EPUB" => 1 "HTML" => 123 "PDF" => 48 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Foro de Residentes</span>" "titulo" => "FR-Ciclosporina como tratamiento de primera línea en las necrólisis epidérmicas" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "601" "paginaFinal" => "603" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "FR-Ciclosporin as a First-Line Treatment in Epidermal Necrolysis" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. Morgado-sCarrasco, X. Fustà-Novell, P. Iranzo" "autores" => array:3 [ 0 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-sCarrasco" ] 1 => array:2 [ "nombre" => "X." "apellidos" => "Fustà-Novell" ] 2 => array:2 [ "nombre" => "P." "apellidos" => "Iranzo" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219019302021" "doi" => "10.1016/j.adengl.2018.01.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019302021?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018304460?idApp=UINPBA000044" "url" => "/00017310/0000011000000007/v1_201909021023/S0001731018304460/v1_201909021023/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219019300484" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.02.010" "estado" => "S300" "fechaPublicacion" => "2019-09-01" "aid" => "2034" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2019;110:e17" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4 "formatos" => array:2 [ "EPUB" => 1 "HTML" => 3 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">e-Images in Dermatology</span>" "titulo" => "Infarcted Giant Skin Tag" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "e17" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Fibroma blando gigante infartado" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:6 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 859 "Ancho" => 2500 "Tamanyo" => 308260 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "E.C. López-Jiménez, R. Ruiz-Rodríguez, I. Sánchez-Carpintero" "autores" => array:3 [ 0 => array:2 [ "nombre" => "E.C." "apellidos" => "López-Jiménez" ] 1 => array:2 [ "nombre" => "R." "apellidos" => "Ruiz-Rodríguez" ] 2 => array:2 [ "nombre" => "I." "apellidos" => "Sánchez-Carpintero" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018303533" "doi" => "10.1016/j.ad.2017.11.022" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018303533?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019300484?idApp=UINPBA000044" "url" => "/15782190/0000011000000007/v1_201909021030/S1578219019300484/v1_201909021030/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219019301271" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.04.013" "estado" => "S300" "fechaPublicacion" => "2019-09-01" "aid" => "2126" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2019;110:599-600" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case for Diagnosis</span>" "titulo" => "Indurated Papules on the Face" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "599" "paginaFinal" => "600" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Pápulas faciales induradas" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:6 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 612 "Ancho" => 850 "Tamanyo" => 95209 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "C. González-Cruz, V. Cabezas, V. García-Patos" "autores" => array:3 [ 0 => array:2 [ "nombre" => "C." "apellidos" => "González-Cruz" ] 1 => array:2 [ "nombre" => "V." "apellidos" => "Cabezas" ] 2 => array:2 [ "nombre" => "V." "apellidos" => "García-Patos" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018305520" "doi" => "10.1016/j.ad.2018.01.018" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018305520?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019301271?idApp=UINPBA000044" "url" => "/15782190/0000011000000007/v1_201909021030/S1578219019301271/v1_201909021030/en/main.assets" ] "en" => array:16 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Resident's Forum</span>" "titulo" => "FR-Ciclosporin as a First-Line Treatment in Epidermal Necrolysis" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "601" "paginaFinal" => "603" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "D. Morgado-Carrasco, X. Fustà-Novell, P. Iranzo" "autores" => array:3 [ 0 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] 1 => array:2 [ "nombre" => "X." "apellidos" => "Fustà-Novell" ] 2 => array:4 [ "nombre" => "P." "apellidos" => "Iranzo" "email" => array:1 [ 0 => "piranzo@clinic.cat" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, España" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "FR-Ciclosporina como tratamiento de primera línea en las necrólisis epidérmicas" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Epidermal necrolysis (EN) is a rare mucocutaneous reaction usually induced by drugs. It is known as Stevens-Johnson syndrome if <10% of the body surface area is affected and toxic epidermal necrolysis if >30% is affected. EN is associated with high mortality, which can be accurately predicted based on the score for toxic epidermal necrolysis (SCORTEN).<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">1</span></a> There is consensus regarding patient hospitalization and management in a specialist intensive care unit, which is associated with improved survival.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">1</span></a> Treatments with corticosteroids, classical immunosuppressants, anti-tumor necrosis factor α (anti-TNF-α) agents, intravenous immunoglobulins (IVIG), and plasmapheresis have been described, despite a lack of clear evidence supporting their efficacy.<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">1,2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">González-Herrada et al<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">3</span></a> recently published the results of a study conducted in 2 burn units in Madrid. In the first unit, at the Hospital Universitario de Getafe (HUG), EN patients were mainly treated with ciclosporin (3 mg/kg/d) until re-epithelialization [<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>]). In the second unit, at the Hospital Universitario La Paz (HULP), patients were mainly treated with IVIG without ciclosporin. These 2 units provided the necessary conditions for a “natural” clinical trial. The study population consisted of 71 EN patients aged 14 years and older. The authors performed 3 types of analysis. The first focused on 42 individuals living in Madrid who were treated at either HUG (n = 23) or HULP (n = 19). Of these, 22 and 4, respectively, were treated with ciclosporin. One patient (4.3%) died at HUG and 6 (31.6%) at HULP. When hospital allocation was included in the analysis as an instrumental variable, the risk of mortality was significantly lower for ciclosporin-treated patients (0.09; 95% confidence interval [95% CI], 0.00–0.49). Next, the authors analyzed a group of 71 patients living in Madrid and elsewhere, 49 of whom were treated with ciclosporin. The mortality rate for this group was significantly lower than that expected based on the SCORTEN (0.42; 95% CI, 0.14–0.99). Finally, the authors performed a meta-analysis of 6 studies involving 134 ciclosporin-treated EN patients (including 49 from the present series). The results revealed that the risk of mortality for this group was significantly lower than that expected based on the SCORTEN (0.41; 95% CI, 0.21–0.80]). The findings indicate that 1 life could be saved by treating only 5.6 EN patients with ciclosporin. While no data on the adverse effects of ciclosporin treatment were available, none of the patients discontinued treatment.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">In their meta-analysis of the efficacy of various immunomodulators in the treatment of EN, Zimmermann et al<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">2</span></a> reported beneficial effects of ciclosporin (odds ratio [OR], 0.1; 95% CI, 0.0–0.4) and a discrete benefit of corticosteroid treatment (OR, 0.7; 95% CI, 0.5–0.97). Mohanty et al<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">9</span></a> recently published the results of a retrospective study (not included in the aforementioned meta-analysis) of 28 EN patients treated with either ciclosporin (n = 19) or with supportive treatment only (n = 9). One patient in the ciclosporin group and 5 in the supportive treatment group died (SCORTEN, 3.11 and 4.73, respectively). The risk of mortality was significantly higher in the supportive treatment group (2.13; 95% CI, 1.02–4.46]).</p><p id="par0020" class="elsevierStylePara elsevierViewall">Early withdrawal of the causative drug and the implementation of advanced support measures are paramount in the treatment of EN. Based on the available evidence (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>), we believe that early ciclosporin treatment is justified. It is imperative that these interventions are carried out quickly: measures not adopted within the first 7 days will be ineffective due to the natural progression of the disease.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">1</span></a></p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2017-12-27" "fechaAceptado" => "2018-01-14" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1149026" "palabras" => array:4 [ 0 => "Ciclosporin" 1 => "Toxic epidermal necrolysis" 2 => "Stevens-Johnson syndrome" 3 => "Epidermal necrolysis" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Morgado-Carrasco D, Fustà-Novell X, Iranzo P. FR-Ciclosporin as a First-Line Treatment in Epidermal Necrolysis. Actas Dermosifiliogr. 2019;110:601–603.</p>" ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Abbreviation: SCORTEN, score for toxic epidermal necrolysis.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Study \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Type of Study \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Ciclosporin Dose \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No. of Patients Treated With Ciclosporin \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No. of Deaths \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No. of Expected Deaths Based on SCORTEN \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Valeyrie-Allanore et al,<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">4</span></a> 2010 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Open prospective clinical trial (2005–2010) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 mg/kg/d for 10 d followed by 2 mg/kg/d for 10 d and then 1 mg/kg/d for 10 d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">29 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.75 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Singh et al,<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">5</span></a> 2013 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Open prospective clinical trial (2011–2012) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 mg/kg/d for 7 d followed by 2 mg/kg/d for 7 d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.11 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Kirchhof et al,<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">6</span></a> 2014 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Retrospective study(2001–2011) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3–5 mg/kg/d for 7 d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.40 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">McKenzie et al,<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">7</span></a> 2016 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Prospective study \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3–5 mg/kg/d for 4–5 d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.54 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lee et al,<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">8</span></a> 2017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Retrospective study(2011–2014) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 mg/kg/d for 10 d followed by 2 mg/kg/d for 10 d and then 1 mg/kg/d for 10 d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gonzalez-Herrada et al,<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">3</span></a> 2017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Retrospective(2001–2010) and prospective study(2011–2015) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 mg/kg/d until re-epithelialization subsequently decreasing by 10 mg/day every 48 h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">49 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mohanty et al,<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">9</span></a> 2017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Retrospective study (2014–2015) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 mg/kg/d for 10 d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.11 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2114534.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Summary of Studies of Ciclosporin Treatment of Epidermal Necrolysis (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis).</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:9 [ 0 => array:3 [ "identificador" => "bib0050" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Creamer" 1 => "S.A. Walsh" 2 => "P. Dziewulski" 3 => "L.S. Exton" 4 => "H.Y. Lee" 5 => "J.K.G. Dart" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.14530" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2016" "volumen" => "174" "paginaInicial" => "1194" "paginaFinal" => "1227" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27317286" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0055" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Zimmermann" 1 => "P. Sekula" 2 => "M. Venhoff" 3 => "E. Motschall" 4 => "J. Knaus" 5 => "M. Schumacher" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamadermatol.2016.5668" "Revista" => array:6 [ "tituloSerie" => "JAMA Dermatol" "fecha" => "2017" "volumen" => "153" "paginaInicial" => "514" "paginaFinal" => "522" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28329382" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0060" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: Evidence from three different approaches" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. González-Herrada" 1 => "S. Rodríguez-Martín" 2 => "L. Cachafeiro" 3 => "V. Lerma" 4 => "O. González" 5 => "J.A. Lorente" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jid.2017.05.022" "Revista" => array:6 [ "tituloSerie" => "J Invest Dermatol" "fecha" => "2017" "volumen" => "137" "paginaInicial" => "2092" "paginaFinal" => "2100" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28634032" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0065" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Valeyrie-Allanore" 1 => "P. Wolkenstein" 2 => "L. Brochard" 3 => "N. Ortonne" 4 => "B. Maître" 5 => "J. Revuz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2010.09863.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol." "fecha" => "2010" "volumen" => "163" "paginaInicial" => "847" "paginaFinal" => "853" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20500799" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0070" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "G.K. Singh" 1 => "M. Chatterjee" 2 => "R. Verma" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4103/0378-6323.116738" "Revista" => array:6 [ "tituloSerie" => "Indian J Dermatol Venereol Leprol." "fecha" => "2013" "volumen" => "79" "paginaInicial" => "686" "paginaFinal" => "692" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23974585" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0075" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M.G. Kirchhof" 1 => "M.A. Miliszewski" 2 => "S. Sikora" 3 => "A. Papp" 4 => "J.P. Dutz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2014.07.016" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol." "fecha" => "2014" "volumen" => "71" "paginaInicial" => "941" "paginaFinal" => "947" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25087214" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0080" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The use of cyclosporine for Stevens–Johnson syndrome and toxic epidermal necrolysis: The University of Louisville experience" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "E. Mckenzie" 1 => "C. Owen" 2 => "J. Callen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "J Am Acad Dermatol." "fecha" => "2016" "volumen" => "74" "paginaInicial" => "AB175" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0085" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "H.Y. Lee" 1 => "S. Fook-Chong" 2 => "H.Y. Koh" 3 => "T. Thirumoorthy" 4 => "S.M. Pang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2016.07.048" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol." "fecha" => "2017" "volumen" => "76" "paginaInicial" => "106" "paginaFinal" => "113" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27717620" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0090" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A record-based study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Mohanty" 1 => "A. Das" 2 => "A. Ghosh" 3 => "A. Sil" 4 => "R.C. Gharami" 5 => "D. Bandyopadhyay" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4103/ijdvl.IJDVL_201_16" "Revista" => array:6 [ "tituloSerie" => "Indian J Dermatol Venereol Leprol" "fecha" => "2017" "volumen" => "83" "paginaInicial" => "312" "paginaFinal" => "316" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28366923" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000011000000007/v1_201909021030/S1578219019302021/v1_201909021030/en/main.assets" "Apartado" => array:4 [ "identificador" => "34945" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Resident's Forum" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011000000007/v1_201909021030/S1578219019302021/v1_201909021030/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019302021?idApp=UINPBA000044" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 16 | 12 | 28 |
| 2024 Octubre | 71 | 39 | 110 |
| 2024 Septiembre | 63 | 23 | 86 |
| 2024 Agosto | 83 | 60 | 143 |
| 2024 Julio | 72 | 23 | 95 |
| 2024 Junio | 67 | 25 | 92 |
| 2024 Mayo | 66 | 36 | 102 |
| 2024 Abril | 74 | 23 | 97 |
| 2024 Marzo | 65 | 25 | 90 |
| 2024 Febrero | 57 | 33 | 90 |
| 2024 Enero | 43 | 32 | 75 |
| 2023 Diciembre | 44 | 21 | 65 |
| 2023 Noviembre | 56 | 37 | 93 |
| 2023 Octubre | 49 | 22 | 71 |
| 2023 Septiembre | 46 | 27 | 73 |
| 2023 Agosto | 30 | 15 | 45 |
| 2023 Julio | 39 | 31 | 70 |
| 2023 Junio | 34 | 28 | 62 |
| 2023 Mayo | 42 | 24 | 66 |
| 2023 Abril | 33 | 21 | 54 |
| 2023 Marzo | 27 | 20 | 47 |
| 2023 Febrero | 32 | 21 | 53 |
| 2023 Enero | 37 | 25 | 62 |
| 2022 Diciembre | 45 | 35 | 80 |
| 2022 Noviembre | 37 | 31 | 68 |
| 2022 Octubre | 24 | 14 | 38 |
| 2022 Septiembre | 17 | 26 | 43 |
| 2022 Agosto | 24 | 45 | 69 |
| 2022 Julio | 24 | 34 | 58 |
| 2022 Junio | 25 | 28 | 53 |
| 2022 Mayo | 26 | 32 | 58 |
| 2022 Abril | 31 | 36 | 67 |
| 2022 Marzo | 41 | 48 | 89 |
| 2022 Febrero | 33 | 22 | 55 |
| 2022 Enero | 34 | 38 | 72 |
| 2021 Diciembre | 35 | 35 | 70 |
| 2021 Noviembre | 42 | 45 | 87 |
| 2021 Octubre | 39 | 61 | 100 |
| 2021 Septiembre | 20 | 44 | 64 |
| 2021 Agosto | 33 | 26 | 59 |
| 2021 Julio | 21 | 21 | 42 |
| 2021 Junio | 24 | 26 | 50 |
| 2021 Mayo | 22 | 37 | 59 |
| 2021 Abril | 69 | 62 | 131 |
| 2021 Marzo | 49 | 29 | 78 |
| 2021 Febrero | 69 | 22 | 91 |
| 2021 Enero | 28 | 12 | 40 |
| 2020 Diciembre | 26 | 21 | 47 |
| 2020 Noviembre | 15 | 12 | 27 |
| 2020 Octubre | 26 | 13 | 39 |
| 2020 Septiembre | 34 | 18 | 52 |
| 2020 Agosto | 23 | 19 | 42 |
| 2020 Julio | 16 | 9 | 25 |
| 2020 Junio | 28 | 23 | 51 |
| 2020 Mayo | 25 | 22 | 47 |
| 2020 Abril | 20 | 10 | 30 |
| 2020 Marzo | 41 | 16 | 57 |
| 2020 Febrero | 4 | 2 | 6 |
| 2019 Septiembre | 2 | 2 | 4 |
Mostrar todo
